Pulmatrix Inc (PULM) Stock Price, Quote & News

Company Profile

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clin...

Industry: Biotechnology

Sector: Healthcare

Phone: (888) 355-4440

Website: www.pulmatrix.com

Address:

945 Concord Street, Suite 1217, Framingham, United States

madan_shatri Jun. 26 at 10:42 PM

$PULM Just 5 minutes back, from Japanese friend : Cullgen上場昨晩、CSRCは6社に対して本土外での株式発行を許可。市場は香港、シンガポールで、NASDAQへの許可はしばらく無いもよう。規制強化などで難易度が高まり、中国企業のNASDAQ上場への申請数も減っています。裏を返せば、許可を得ればCullgenが優秀である証拠になると考えます。拒む理由は？🐱 Cullgen Listing Last night, the CSRC gave six companies permission to issue shares outside the mainland. The markets are Hong Kong and Singapore, and it seems that permission to list on NASDAQ will not be granted for some time. The number of Chinese companies applying to list on NASDAQ has decreased due to the increasing difficulty of regulations. On the other hand, if permission is granted, it will be proof that Cullgen is excellent. Why are they refusing? 🐱 🤔🤔

0 · Reply

Igotzthis Jun. 26 at 8:52 PM

$PULM Hopefully we get some news tomorrow. Talk about waiting until the last day. Remember Monday is the last day of the half. I wonder how much it will cost Cullgen not to do the merger on Monday. Just more to go towards my dividend check. All good!!!

1 · Reply

hippo_hungry Jun. 26 at 8:23 PM

$PULM when I have to have “faith” in a stock .. you know it’s a turd lol

1 · Reply

HomeRunHitterXXXXX Jun. 26 at 7:48 PM

$PULM doesn’t look like this is happening before the 1st

1 · Reply

hippo_hungry Jun. 26 at 6:35 PM

$PULM negative news tomorrow?

1 · Reply

Igotzthis Jun. 26 at 2:20 PM

$PULM don’t forget this coming Monday is merger Monday!!! It’s going to happen. Just have faith.

0 · Reply

anatoma1 Jun. 25 at 10:15 PM

$PULM I am guessing the listing will be on Friday the 27th, news tomorrow morning. On Monday CUGN will release data. Makes sense.

0 · Reply

HomeRunHitterXXXXX Jun. 25 at 8:14 PM

$PULM last minute sell by scum mm to close red

0 · Reply

Kasper11 Jun. 25 at 6:17 PM

$PULM hopefully some positive news tomorrow, so we can get some closure on this whole thing.

0 · Reply

HomeRunHitterXXXXX Jun. 25 at 4:51 PM

$PULM

0 · Reply

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 9, 2025, 4:00 PM EDT - 6 weeks ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Mar 21, 2025, 8:05 AM EDT - 3 months ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Nov 15, 2024, 8:00 AM EST - 7 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

ENTO

Nov 13, 2024, 9:00 AM EST - 8 months ago

Pulmatrix and Cullgen Announce Proposed Merger

Nov 8, 2024, 10:26 AM EST - 8 months ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 9:05 AM EDT - 11 months ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 8:45 AM EDT - 1 year ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MNKD

May 15, 2024, 9:35 AM EDT - 1 year ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 10, 2024, 8:05 AM EDT - 1 year ago

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

Mar 28, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Jan 8, 2024, 9:00 AM EST - 1 year ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Nov 9, 2023, 9:05 AM EST - 1 year ago

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 19, 2023, 9:05 AM EDT - 1 year ago

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Aug 23, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Aug 10, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 11, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Jun 15, 2023, 9:20 AM EDT - 2 years ago

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

May 24, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 12, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 2, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Supports World Asthma Day 2023

Mar 30, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Feb 6, 2023, 9:10 AM EST - 2 years ago

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Jan 25, 2023, 9:05 AM EST - 2 years ago

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Jan 23, 2023, 9:05 AM EST - 2 years ago

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Jan 4, 2023, 9:05 AM EST - 2 years ago

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Nov 10, 2022, 9:05 AM EST - 2 years ago

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 26, 2022, 9:00 AM EDT - 2 years ago

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Aug 8, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 12, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

May 12, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Mar 29, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Mar 21, 2022, 12:45 PM EDT - 3 years ago

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Mar 21, 2022, 8:05 AM EDT - 3 years ago

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Mar 17, 2022, 4:05 PM EDT - 3 years ago

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Mar 1, 2022, 9:00 AM EST - 3 years ago

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Feb 24, 2022, 4:05 PM EST - 3 years ago

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Feb 1, 2022, 9:00 AM EST - 3 years ago

Pulmatrix Issues Letter to Stockholders

Dec 17, 2021, 4:30 PM EST - 3 years ago

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Dec 15, 2021, 8:00 AM EST - 3 years ago

Pulmatrix Announces $6.75 Million Registered Direct Offering

Nov 10, 2021, 4:15 PM EST - 3 years ago

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 9, 2021, 9:00 AM EST - 3 years ago

Pulmatrix Announces Resolution of Contract Dispute with Cipla

Aug 10, 2021, 9:10 AM EDT - 4 years ago

Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update

Jul 27, 2021, 10:00 AM EDT - 4 years ago

Pulmatrix appoints Director Anand Varadan

May 11, 2021, 4:35 PM EDT - 4 years ago

Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update

Apr 15, 2021, 9:15 AM EDT - 4 years ago

Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine

Apr 12, 2021, 5:41 PM EDT - 4 years ago

Corrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio

madan_shatri Jun. 26 at 10:42 PM

0 · Reply

Igotzthis Jun. 26 at 8:52 PM

1 · Reply

hippo_hungry Jun. 26 at 8:23 PM

$PULM when I have to have “faith” in a stock .. you know it’s a turd lol

1 · Reply

HomeRunHitterXXXXX Jun. 26 at 7:48 PM

$PULM doesn’t look like this is happening before the 1st

1 · Reply

hippo_hungry Jun. 26 at 6:35 PM

$PULM negative news tomorrow?

1 · Reply

Igotzthis Jun. 26 at 2:20 PM

$PULM don’t forget this coming Monday is merger Monday!!! It’s going to happen. Just have faith.

0 · Reply

anatoma1 Jun. 25 at 10:15 PM

$PULM I am guessing the listing will be on Friday the 27th, news tomorrow morning. On Monday CUGN will release data. Makes sense.

0 · Reply

HomeRunHitterXXXXX Jun. 25 at 8:14 PM

$PULM last minute sell by scum mm to close red

0 · Reply

Kasper11 Jun. 25 at 6:17 PM

$PULM hopefully some positive news tomorrow, so we can get some closure on this whole thing.

0 · Reply

HomeRunHitterXXXXX Jun. 25 at 4:51 PM

$PULM

0 · Reply

DietrichAF Jun. 25 at 4:15 PM

$PULM

0 · Reply

HomeRunHitterXXXXX Jun. 25 at 3:32 PM

$PULM crooked trading

0 · Reply

Gugger Jun. 25 at 3:28 PM

$PULM Same bullshit today, up to $8 and now almost $6 🤡

1 · Reply

hippo_hungry Jun. 25 at 3:14 PM

$PULM halted after 93k trade

1 · Reply

hippo_hungry Jun. 25 at 3:13 PM

$PULM lol someone tried to move this with heavy block trades … denied !!!

0 · Reply

HaltTradeAlert Jun. 25 at 3:12 PM

$PULM Halt Time: 11:11:01 Issue Symbol: PULM Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!

0 · Reply

HomeRunHitterXXXXX Jun. 25 at 11:47 AM

$PULM

0 · Reply

hippo_hungry Jun. 24 at 5:02 PM

$PULM where is that bozo Synchronization.. he’s gotta be down 99% lol .. he said this technology was supposed to change the world. 😂 bozo

0 · Reply

HomeRunHitterXXXXX Jun. 24 at 3:57 PM

$PULM dumb dumb here early I see

0 · Reply

DietrichAF Jun. 24 at 2:44 PM

$PULM Where is the monday merger moron? The gal who is always hype and always wrong

3 · Reply

Igotzthis Jun. 24 at 2:42 PM

$PULM I think Pulmatrix and Cullgen are going to be very busy this weekend. It being Merger Monday!!! Go Pulmatrix.

1 · Reply

Busstamove Jun. 24 at 1:43 PM

$PULM found liquidity yesterday somehow (binny ;) where and will we find it today? She’s almost home.

1 · Reply

Market Cap	24.97M
Revenue (ttm)	7.81M
Net Income (ttm)	-6.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-88.86%
Debt to Equity Ratio	0.00

Volume	7,900
Avg Vol	35,044
Day's Range	N/A - N/A
Shares Out	3.65M
Stochastic %K	51%
Beta	1.45
Analysts	Strong Buy
Price Target	$10.00